Monistat-Derm en es it fr

Monistat-Derm Brand names, Monistat-Derm Analogs

Monistat-Derm Brand Names Mixture

  • No information avaliable

Monistat-Derm Chemical_Formula


Monistat-Derm RX_link

Monistat-Derm fda sheet

Monistat-Derm msds (material safety sheet)

Monistat-Derm Synthesis Reference

No information avaliable

Monistat-Derm Molecular Weight

498.568 g/mol

Monistat-Derm Melting Point

No information avaliable

Monistat-Derm H2O Solubility

Soluble (about 10% weight-to-volume) in distilled water at room temperature as HCl salt.

Monistat-Derm State


Monistat-Derm LogP


Monistat-Derm Dosage Forms

Tablets (scored, coated, containing 7.5 mg or 15 mg of moexipril hydrochloride for oral administration)

Monistat-Derm Indication

For treatment of patients with hypertension.

Monistat-Derm Pharmacology

Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.

Monistat-Derm Absorption

Moexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces Cmax and AUC by about 70% and 40% respectively after the ingestion of a low-fat breakfast or by 80% and 50% respectively after the ingestion of a high-fat breakfast.

Monistat-Derm side effects and Toxicity

Human overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg.

Monistat-Derm Patient Information

Monistat-Derm Organisms Affected

Humans and other mammals